Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study

Leo I. Gordon, Arturo Molina, Thomas Elmer Witzig, Christos Emmanouilides, Andrew Raubtischek, Mohamed Darif, Russell J. Schilder, Greg Wiseman, Christine A. White

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)4429-4431
Number of pages3
JournalBlood
Volume103
Issue number12
DOIs
StatePublished - Jun 15 2004

Fingerprint

Radioimmunotherapy
B-Cell Lymphoma
Cells
Yttrium
Refractory materials
Maximum Tolerated Dose
Lymphoma, Large B-Cell, Diffuse
Non-Hodgkin's Lymphoma
B-Lymphocytes
Education
ibritumomab tiuxetan

ASJC Scopus subject areas

  • Hematology

Cite this

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : Long-term follow-up of a phase 1/2 study. / Gordon, Leo I.; Molina, Arturo; Witzig, Thomas Elmer; Emmanouilides, Christos; Raubtischek, Andrew; Darif, Mohamed; Schilder, Russell J.; Wiseman, Greg; White, Christine A.

In: Blood, Vol. 103, No. 12, 15.06.2004, p. 4429-4431.

Research output: Contribution to journalArticle

Gordon, LI, Molina, A, Witzig, TE, Emmanouilides, C, Raubtischek, A, Darif, M, Schilder, RJ, Wiseman, G & White, CA 2004, 'Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study', Blood, vol. 103, no. 12, pp. 4429-4431. https://doi.org/10.1182/blood-2003-11-3883
Gordon, Leo I. ; Molina, Arturo ; Witzig, Thomas Elmer ; Emmanouilides, Christos ; Raubtischek, Andrew ; Darif, Mohamed ; Schilder, Russell J. ; Wiseman, Greg ; White, Christine A. / Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma : Long-term follow-up of a phase 1/2 study. In: Blood. 2004 ; Vol. 103, No. 12. pp. 4429-4431.
@article{a43276cddb4a4cf49606e89990da07e7,
title = "Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study",
abstract = "We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29{\%}, 22{\%}, and 22{\%}, respectively (overall response rate 73{\%}, 51{\%} in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24{\%} of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.",
author = "Gordon, {Leo I.} and Arturo Molina and Witzig, {Thomas Elmer} and Christos Emmanouilides and Andrew Raubtischek and Mohamed Darif and Schilder, {Russell J.} and Greg Wiseman and White, {Christine A.}",
year = "2004",
month = "6",
day = "15",
doi = "10.1182/blood-2003-11-3883",
language = "English (US)",
volume = "103",
pages = "4429--4431",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma

T2 - Long-term follow-up of a phase 1/2 study

AU - Gordon, Leo I.

AU - Molina, Arturo

AU - Witzig, Thomas Elmer

AU - Emmanouilides, Christos

AU - Raubtischek, Andrew

AU - Darif, Mohamed

AU - Schilder, Russell J.

AU - Wiseman, Greg

AU - White, Christine A.

PY - 2004/6/15

Y1 - 2004/6/15

N2 - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.

AB - We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu), and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean time to progression (TTP) and duration of response (DR) in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg [14.8 MBq/kg]), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of more than 3 years. Long-term responders (> 5 years) have been identified. Ibritumomab tiuxetan produces durable responses in patients with indolent and diffuse large B-cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=2942595713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942595713&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-11-3883

DO - 10.1182/blood-2003-11-3883

M3 - Article

C2 - 15016644

AN - SCOPUS:2942595713

VL - 103

SP - 4429

EP - 4431

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -